



US009511032B2

(12) **United States Patent**
Lickrish et al.

(10) **Patent No.:** **US 9,511,032 B2**
(45) **Date of Patent:** ***Dec. 6, 2016**

(54) **COMPOSITIONS FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER**

(71) Applicant: **Ironshore Pharmaceuticals & Development, Inc.**, Camana Bay (KY)

(72) Inventors: **David Lickrish**, Camana Bay (KY);
Feng Zhang, Pflugerville, TX (US)

(73) Assignee: **Ironshore Pharmaceuticals & Development, Inc.**, Camana Bay (KY)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/076,253**

(22) Filed: **Mar. 21, 2016**

(65) **Prior Publication Data**

US 2016/0199312 A1 Jul. 14, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/841,428, filed on Aug. 31, 2015, now Pat. No. 9,289,394, which is a continuation of application No. 14/255,529, filed on Apr. 17, 2014, now Pat. No. 9,119,809, which is a continuation-in-part of application No. 14/230,053, filed on Mar. 31, 2014, now Pat. No. 8,927,010, and a continuation-in-part of application No. 14/230,067, filed on Mar. 31, 2014, now Pat. No. 8,916,588, said application No. 14/230,053 is a continuation-in-part of application No. 13/429,292, filed on Mar. 23, 2012, now Pat. No. 9,028,868, said application No. 14/230,067 is a continuation-in-part of application No. 13/429,292, filed on Mar. 23, 2012, now Pat. No. 9,028,868.

(60) Provisional application No. 61/466,684, filed on Mar. 23, 2011, provisional application No. 61/561,763, filed on Nov. 18, 2011, provisional application No. 61/591,129, filed on Jan. 26, 2012, provisional application No. 61/827,489, filed on May 24, 2013.

(51) **Int. Cl.**
A61K 9/50 (2006.01)
A61K 31/137 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 9/5073** (2013.01); **A61K 9/5026** (2013.01); **A61K 9/5042** (2013.01); **A61K 31/137** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,309,405 A 1/1982 Guley et al.
4,687,660 A 8/1987 Baker et al.
4,904,476 A 2/1990 Mehta et al.
4,963,365 A 10/1990 Samejima et al.
5,137,733 A 8/1992 Noda et al.
5,260,068 A 11/1993 Chen
5,266,331 A 11/1993 Oshlack et al.
5,496,561 A 3/1996 Okada et al.
5,508,042 A 4/1996 Oshlack et al.
5,549,912 A 8/1996 Oshlack et al.
5,656,295 A 8/1997 Oshlack et al.
5,658,590 A 8/1997 Heiligenstein et al.
5,837,284 A 11/1998 Mehta et al.
5,874,090 A 2/1999 Baker et al.
5,908,850 A 6/1999 Zeitlin et al.
5,958,446 A 9/1999 Miranda et al.
6,210,705 B1 4/2001 Mantelle et al.
6,228,398 B1 5/2001 Devane et al.
6,254,887 B1 7/2001 Miller et al.
6,287,599 B1 9/2001 Burnside et al.
6,322,819 B1 11/2001 Burnside et al.
6,344,215 B1 2/2002 Bettman et al.
6,348,211 B1 2/2002 Mantelle et al.
6,355,656 B1 3/2002 Zeitlin et al.
6,384,020 B1 5/2002 Flanner et al.
6,500,459 B1 12/2002 Chhabra et al.
6,524,620 B2 2/2003 Chen et al.
6,528,530 B2 3/2003 Zeitlin et al.
6,569,456 B2 5/2003 Faour et al.
6,605,300 B1 8/2003 Burnside et al.
6,627,223 B2 9/2003 Percel et al.
6,635,284 B2 10/2003 Mehta et al.
6,730,325 B2 5/2004 Devane et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 2 718 639 10/2009
EP 1 782 798 5/2007
GB 2 230 442 10/1990
WO WO 96/41617 12/1996
WO WO 97/27176 7/1997

(Continued)

OTHER PUBLICATIONS

Extended European Search Report dated Aug. 26, 2014.

International Search Report dated Jul. 3, 2012.

Aoyama, T., et al., "Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers," Eur. J. Clin. Pharmacol (1993) 44: 79-84.

(Continued)

Primary Examiner — Frederick Krass

Assistant Examiner — Michael P Cohen

(74) *Attorney, Agent, or Firm* — Vinson & Elkins LLP

(57) **ABSTRACT**

Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) and other CNS stimulant responsive conditions include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by an extended release.

25 Claims, 29 Drawing Sheets